Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · The Lancet · 2,820 citations
https://doi.org/10.1016/s0140-6736(19)31149-3
B
Byeong‐Keuk Kim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
581
Papers
15.0K
Citations
50
h-index
220
i10-index
Byeong‐Keuk Kim is an academic researcher from Ewha Womans University. The author has contributed to research in topics: Coronary Interventions and Diagnostics & Antiplatelet Therapy and Cardiovascular Diseases & Acute Myocardial Infarction Research. The author has an h-index of 50, co-authored 494 publications.
ORCID: 0000-0003-2493-066XPapers by this author
worksA New Strategy for Discontinuation of Dual Antiplatelet Therapy
2012 · Journal of the American College of Cardiology · 637 citations
https://doi.org/10.1016/j.jacc.2012.06.043
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
2019 · The Lancet · 600 citations
https://doi.org/10.1016/s0140-6736(19)31150-x
Effect of Intravascular Ultrasound–Guided vs Angiography-Guided Everolimus-Eluting Stent Implantation
2015 · JAMA · 578 citations
https://doi.org/10.1001/jama.2015.15454
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome
2020 · JAMA · 524 citations
https://doi.org/10.1001/jama.2020.7580
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting
2017 · Journal of the American College of Cardiology · 142 citations
https://doi.org/10.1016/j.jacc.2017.02.029
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat